The detectability of psilocybin and psilocin, the psychoactive compounds in psychedelic mushrooms, through standard drug screening methods is limited. Routine drug tests typically do not include assays specifically designed to identify these substances. Therefore, the presence of these compounds is unlikely to be revealed in a standard screening.
Traditional drug testing panels are designed to detect commonly abused substances such as opioids, amphetamines, cocaine, and cannabis. The metabolic processes and relatively short half-lives of psilocybin and psilocin, coupled with their comparatively less frequent use, contribute to their exclusion from standard drug test panels. Historical context also plays a role, as the societal focus has been on substances deemed more prevalent and problematic in terms of addiction and public health.